PDCD1 and neoplasm: The rationale for PARPi in combination with PD-1/PD-L1 inhibitors mainly involves four aspects: tumor neoantigen production, increasing tumor-infiltrating lymphocytes (TILs), enhanced antigen presentation and regulation of PD-L1 and other molecules in tumor microenvironment [5].